6th Annual Gene Therapy Immunogenicity

Topics

• The impact of innate and anti-transgene immunogenicity on AAV vector-mediated gene transfer with Genethon
• Developing an immune evasive AAV for repeat dosing
• Performances of biosafety analytical assays commonly used in gene therapy development
• Strategies to monitor anti-AAV cell-based transduction inhibition assay supporting clinical trials with Sangamo Therapeutics
• How to define the seroprevalence and titer of pre-existing antibodies with age and geographical location with Novartis
• Immunogenicity risk assessment for AAV-based gene therapies with Roche
• Regulatory considerations for immune responses to gene therapies with the FDA